Piper Sandler Reiterates Overweight on Camp4 Therapeutics, Raises Price Target to $15

Benzinga Newsdesk www.benzinga.com Positive 63.0%

Neg 0% Neu 0% Pos 63%

Piper Sandler analyst Edward Tenthoff reiterates Camp4 Therapeutics (NASDAQ:CAMP) with a Overweight and raises the price target from $12 to $15.